Detection of anthracycline-induced cardiotoxicity using perfusion-corrected 99mTc sestamibi SPECT by Safee, Zaitulhusna M. et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1038/s41598-018-36721-5
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Safee, Z. M., Baark, F., Waters, E. C. T., Veronese, M., Pell, V. R., Clark, J. E., ... Southworth, R. (2019).
Detection of anthracycline-induced cardiotoxicity using perfusion-corrected 99mTc sestamibi SPECT. Scientific
Reports, 9(1), 216-227. https://doi.org/10.1038/s41598-018-36721-5
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
1SCIENtIFIC RepoRTs |           (2019) 9:216  | DOI:10.1038/s41598-018-36721-5
www.nature.com/scientificreports
Detection of anthracycline-induced 
cardiotoxicity using perfusion-
corrected 99mTc sestamibi SPECT
Zaitulhusna M. Safee1, Friedrich Baark1, Edward C. T. Waters1, Mattia Veronese  2, 
Victoria R. Pell1, James E. Clark3, Filipa Mota1, Lefteris Livieratos1, Thomas R. Eykyn1, 
Philip J. Blower1 & Richard Southworth  1
By the time cardiotoxicity-associated cardiac dysfunction is detectable by echocardiography it is often 
beyond meaningful intervention. 99mTc-sestamibi is used clinically to image cardiac perfusion by single 
photon emission computed tomography (SPECT) imaging, but as a lipophilic cation its distribution is 
also governed by mitochondrial membrane potential (ΔΨm). Correcting scans for variations in perfusion 
(using a ΔΨm-independent perfusion tracer such as (bis(N-ethoxy-N-ethyldithiocarbamato)nitrido 
99mTc(V)) (99mTc-NOET) could allow 99mTc-sestamibi to be repurposed to specifically report on ΔΨm as 
a readout of evolving cardiotoxicity. Isolated rat hearts were perfused within a γ-detection apparatus 
to characterize the pharmacokinetics of 99mTc-sestamibi and 99mTc-NOET in response to mitochondrial 
perturbation by hypoxia, ionophore (CCCP) or doxorubicin. All interventions induced 99mTc-sestamibi 
washout; hypoxia from 24.9 ± 2.6% ID to 0.4 ± 6.2%, CCCP from 22.8 ± 2.5% ID to −3.5 ± 3.1%, and 
doxorubicin from 23.0 ± 2.2% ID to 17.8 ± 0.7, p < 0.05. Cardiac 99mTc-NOET retention (34.0 ± 8.0% ID) 
was unaffected in all cases. Translating to an in vivo rat model, 2 weeks after bolus doxorubicin injection, 
there was a dose-dependent loss of cardiac 99mTc-sestamibi retention (from 2.3 ± 0.3 to 0.9 ± 0.2 
ID/g with 10 mg/kg (p < 0.05)), while 99mTc-NOET retention (0.93 ± 0.16 ID/g) was unaffected. 99mTc-
NOET therefore traps in myocardium independently of the mitochondrial perturbations that induce 
99mTc-sestamibi washout, demonstrating proof-of-concept for an imaging approach to detect evolving 
cardiotoxicity.
Anthracyclines are a first in line therapy used to treat numerous malignancies including leukaemia, lymphoma, 
myeloma, lung, ovarian, gastric, thyroid and breast carcinoma1,2. However, they are highly toxic to the heart, 
inducing coronary heart disease, valvular heart disease, cardiomyopathy, and heart failure3,4. This is of particular 
concern for paediatric cancer patients, cardiovascular disease being the leading non-malignant cause of death in 
long-term survivors of childhood cancer5. Anthracycline-induced cardiac injury is generally dose-dependent6 
and the severity and rate of progression of cardiotoxicity varies greatly between patients being dependent on age7, 
gender8, co-existing disease7, prior or concurrent chemo- or radiotherapy9,10, and rate and frequency of drug 
administration11. Personalizing chemotherapeutic dose while minimizing cardiac damage is highly challenging12, 
the timeline of cardiotoxicity development can vary anything from weeks to years following chemotherapy2, 
which is further confounded by an asymptomatic period prior to a progressive functional deterioration13.
Cardiotoxicity is routinely monitored by functional measurements using echocardiography or multigated 
acquisition (MUGA) scanning14. However, anthracycline cardiotoxicity is initiated at the subcellular level, com-
monly associated with mitochondrial dysfunction and elevated oxidative stress15–17. By the time cardiotoxic-
ity manifests as contractile dysfunction, it is often too late to intervene beyond managing the heart failure18. 
Non-invasive in vivo molecular imaging approaches, targeted at mitochondrial dysfunction, may be able to high-
light evolving cardiotoxicity earlier and with greater sensitivity than functional imaging approaches currently 
employed.
Fluorescent lipophilic cations like tetramethylrhodamine ethyl ester (TMRE) and Rhodamine123 are exten-
sively used experimentally to report on mitochondrial membrane potential (ΔΨm) in cell culture and isolated 
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tissue preparations. However, they have limited utility in vivo due to poor depth penetration, and lack of whole 
body scanning. On the other hand, 99mTc-sestamibi, (99mTc-MIBI) is routinely used clinically to visualize cardiac 
perfusion using SPECT, but as a lipophilic cation19 its myocardial distribution is more correctly a function of 
both regional perfusion and ΔΨm20. If cardiac retention of 99mTc-MIBI or other SPECT and PET lipophilic cat-
ions could be corrected for perfusion, either by pharmacokinetic modelling or using a parallel “true” perfusion 
imaging agent which is independent of mitochondrial function or other metabolic parameters, it may be possible 
to develop tracers that report on cardiac ΔΨm as a non-invasive clinical readout of mitochondrial cardiotoxic-
ity. Such an approach would provide more responsive, accurate, personalized treatment regimes, or could be 
employed as an imaging biomarker of novel cardioprotective regimes or therapies.
In this study, we investigated the possibility of pairing 99mTc-MIBI with 99mTc-NOET (bis
(N-ethoxy-N-ethyldithiocarbamato)nitrido 99mTc(V)), which is a lipophilic uncharged (and therefore ΔΨm inde-
pendent) “true” perfusion imaging agent21 to report on cardiotoxicity by SPECT.
Materials and Methods
Reagents and gas mixtures. All reagents were purchased from Sigma Aldrich (Poole, Dorset, UK) unless 
otherwise stated. All gas mixtures were purchased from BOC, UK. Specialist gas mixtures were certified by the 
manufacturer.
Animals. Male Wistar rats (220–240 g, B&K Universal, UK) were used for all experiments in accordance 
with the Animals (Scientific Procedures) Act, UK (1986). All experimental procedures were approved by King’s 
College London’s local Animal Care and Ethics Committee, and carried out in accordance with Home Office reg-
ulations as detailed in the Guidance on the Operation of Animals (Scientific Procedures) Act 1986.
Radiopharmaceutical preparations. 99mTc-MIBI was prepared from commercial cold kits (Mallinckrodt 
Pharmaceuticals) reconstituted with saline (100MBq/ml) from a 99Mo/99mTc generator and supplied by the radi-
opharmacy at Guy’s Hospital, UK. NOET ligand, DIMEB and Vial A were a generous gift from Roberto Pasqualini 
(co-inventor of 99mTc-NOET)22. 99mTc-NOET was prepared fresh before each use.
The triple γ-detection system. We have described the design of our triple γ-detection system, and its use 
for pharmacokinetic characterization of radiotracers in the Langendorff perfused heart previously23,24. Briefly, it 
comprises three orthogonal lead-collimated Na/I γ-detectors arrayed around a perfusion apparatus, positioned 
(i) 3 cm downstream of a radiotracer injection port on the arterial line, 15 cm upstream of the heart cannula (to 
provide a radiotracer input function), (ii) directly opposite the heart (to monitor cardiac retention), and (iii) over 
the venous outflow line (to provide an output function). Each detector was connected to a modified GinaSTAR™ 
ITLC system running Gina™ software for real-time data collection (Raytest Ltd, UK).
Langendorff Perfusion and radiometric analysis. Rats (n = 5/group) were anesthetized with Sagatal, 
(Rhone Merieux, 100 mg intraperitoneal), heparinised (200 IU intraperitoneal), and their hearts were excised 
and perfused in Langendorff mode with modified Krebs-Henseleit buffer (KHB) 37 °C containing NaCl 
(118.5 mM), NaHCO3 (25 mM), D-glucose (11 mM), KCl (8 mM), CaCl2 (2.5 mM), MgSO4 (1.2 mM), and 
Na2-ethylenediamine tetraacetic acid (0.5 mM) at 37 °C gassed with 95%O2/5%CO2 at 14 mL/min constant flow23, 
which on average delivered an initial coronary perfusion pressure of 74 mmHg (Supplemental Fig. 4). Buffer oxy-
gen saturation was monitored by an arterial line fibre-optic oxygen/temperature probe (Oxford Optronix Ltd). 
Contractile function was monitored with an intraventricular balloon set to an initial end diastolic pressure of 
6–8 mm Hg connected to a Powerlab system running Labchart software (AD Instruments Ltd).
Radiotracer boluses (4MBq in ~100 µl) were injected into the arterial line, and their passage through the triple 
γ-detector system evaluated. Cardiac tracer retention was calculated as the activity at 15 minutes post injection 
as a percentage of the peak cardiac activity immediately after each injection23. All curve fitting was performed 
using MATLAB (MathWorks®). Data were normalized to the maximum peak counts after each injection and 
corrected for decay and cardiac activity immediately prior to each bolus injection. Washout curves described by 
the temporal data f(t) were fitted to tri-exponential (Eq. 1) or bi-exponential functions (Eq. 2) as determined most 
appropriate using least squares fitting24:
= + +− − −f(t) Ae Ce Fe (1)bt dt pt
= +− −f(t) Ae Fe (2)bt pt
where b, d and p were the fast, intermediate and slow clearance rate constants (FCR, ICR and SCR, respectively) 
and A, C and F were their respective weights.
Experimental protocols. Langendorff experiments consisted of a 10-minute stabilization period, followed 
by a 30-minute control perfusion period, and then a 50-minute intervention period. Radiotracer boluses were 
injected after 10 minutes of control perfusion, and then 5 and 25 minutes after the induction of each intervention. 
The effect of cardiac hypoxia on tracer pharmacokinetics was investigated by switching perfusion buffer to a 
second reservoir containing KHB equilibrated with 95%N2/5% CO2. The effect of mitochondrial depolarization 
was investigated using the ionophore carbonyl cyanide m-chlorophenyl hydrazone (CCCP) at 0, 150, 300 and 
600 nmol/L infused into the arterial line via a side arm. The direct acute effect of doxorubicin administration at 0, 
1, 10 or 100 μmol/l was evaluated in the same manner. To determine our capacity to detect doxorubicin-induced 
cardiotoxicity in vivo, two additional studies were performed. Following baseline in vivo measurement of cardiac 
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geometry and contractile function by echocardiography, rats were injected with doxorubicin (intraperitoneal; 
saline vehicle, 1, 5, or 10 mg/kg in 100 μl). Two weeks later, a follow-up echocardiographic assessment was per-
formed. In the first study, hearts were excised and Langendorff-perfused as above. After a 20 min stabilization 
period, a bolus of either 99mTc-MIBI or 99mTc-NOET was injected into the arterial perfusion line, and cardiac 
retention and washout were determined using the triple γ-detection system as before. In the second study, ani-
mals were injected with either 99mTc-MIBI or 99mTc-NOET (100 MBq in 50 μl via tail vein). 3 hours later, ani-
mals were culled, and tracer biodistribution (including cardiac retention) was determined by a standard ex vivo 
cut-and-count approach. The apex of the myocardium was dissected in situ, from which 2 mm cubes of ventricu-
lar tissue were cut and immediately immersed in fixative (2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer 
(pH 7.4)) for electron microscopy. The remainder of the myocardium was freeze-clamped with liquid nitrogen 
and stored at −80 °C prior to biochemical analysis.
Echocardiography. Echocardiograms were obtained using a Vevo 770 System (VisualSonics, Canada) with a 
RMV-710B transducer running at 25 MHz. B-mode imaging was used to obtain high-resolution two-dimensional 
cross-sections in long- or short-axis view. M-Mode imaging then interrogated a line of interest at the level of 
a papillary muscle to measure the thickness of the interventricular septum in diastole (IVSs), left ventricular 
internal diameter in diastole (LVIDd), left ventricular internal diameter in systole (LVIDs) and left ventricular 
posterior wall thickness in diastole (LVPWd). These measurements were used to calculate left ventricular frac-
tional shortening (FS) and ejection fraction (EF) in accordance with American Society for Echocardiography 
Guidelines.
Electron microscopy. Samples were fixed, stained and sectioned as previously described25. Images were 
captured using a Fei Tecnai 12 transmission electron microscope at an accelerating voltage of 80 kV. To ensure 
that there was no bias in our measurements, we used “systematic random sampling” to obtain 60 images/heart, as 
previously described26. Mitochondrial area and number were calculated using our previously described stereo-
logical approach, while the percentage of damaged mitochondria in each field of view were counted and averaged 
across all sections.
High energy phosphate assay. Cardiac high energy phosphate levels were assayed by reversed-phase 
HPLC according to Teerlink et al.27 using a 5 µm Eclipse XDB-C18 15 cm × 4.6 mm column (Agilent 
Technologies). ATP and ADP were quantified by measuring the UV peak area at 210 nm compared to corre-
sponding standards, expressed as µmol/g wet tissue.
Citrate Synthase Assay. Citrate synthase was measured spectrophotometrically as previously described28. 
50 mg of tissue was homogenized in 1 ml STE buffer (250 mM sucrose, 5 mM Tris, 1 mM EDTA, pH 7.4) and 
centrifuged for 1 min at 6000 rpm, 4 °C. The supernatant was removed and protein concentration determined 
by BCA assay. Protein (20 μg) was incubated for 2 min in a 1 ml cuvette thermostatted to 30 °C containing 900 µl 
100 mM Tris HCl, pH 8.0, 0.1% (v/v) Triton-X-100, 0.04 mg/ml DTNB, and 0.3 mg/ml acetyl CoA. Absorbance 
was measured at 412 nm every 2 seconds for 2 min on a SPECTROstar Nano spectrophotometer. Oxaloacetic 
acid (0.05 mg/ml) was added and change in absorbance followed for 3 min. Background acetyl CoA hydrolysis 
was corrected for by subtracting the rate prior to oxaloacetic acid addition from the rate post addition. Data were 
normalized to sample protein content and expressed as change in absorbance/min/μg protein. Each sample was 
run in triplicate and averaged.
Data analysis. All group allocations and analyses were performed randomized and blinded, with the iden-
tities of the tissue samples and images revealed only after the data analysis was complete. Statistical analysis 
was performed using GraphPad Prism® (GraphPad, USA). All values are expressed as mean ± SD. All data were 
analyzed using a one-way ANOVA with Bonferroni correction post-hoc test or Dunnett’s test when multiple 
comparisons were made to a control group.
Results
Langendorff tracer retention in response to mitochondrial perturbation. Hypoxia. During 
normoxic perfusion, 24.9 ± 2.6% of each injected 99mTc-MIBI dose was stably trapped in the heart (Fig. 1). 
Hypoxic buffer perfusion caused this trapping to fall to 11.3 ± 5.2% (p < 0.05) after 5 minutes and 0.4 ± 6.2% 
after 45 minutes (p < 0.05). 99mTc-NOET was stably retained within the myocardium during aerobic perfusion 
(34 ± 8% of injected dose), and its retention was unaffected by hypoxic buffer perfusion. 99mTc-MIBI time activity 
curves were best fitted by a tri-exponential equation. The FCR (16.9 ± 3.9 min−1) and its amplitude (0.65 ± 0.06) 
were unaffected by perfusion with hypoxic buffer (Supplementary Fig. 1). The ICR (1.67 ± 0.62 min−1) and its 
amplitude (0.08 ± 0.02) both approximately doubled with hypoxic buffer perfusion (p < 0.05), while the SCR 
(0.010 ± 0.002 min−1) increased 17-fold (p < 0.05). Its amplitude (0.27 ± 0.03) was not affected. 99mTc-NOET 
kinetics were best fit with a bi-exponential equation. The initial FCR for 99mTc-NOET was 30.05 ± 4.7 min−1 with 
an amplitude of 0.71 ± 0.13. This did not change significantly during continued normoxic or hypoxic buffer per-
fusion. The normoxic SCR was 0.003 ± 0.002 min−1, which approximately doubled during hypoxia (p < 0.05), 
while its amplitude (0.389 ± 0.128) did not change.
CCCP infusion. Increasing concentrations of CCCP caused a progressive loss of cardiac 99mTc-MIBI trapping, 
falling from 22.8 ± 2.5% to 10.5 ± 2.2% and 6.7 ± 2.5% after 5 minutes of perfusion with 150 and 300 nM CCCP 
respectively (Fig. 2). After 5 minutes of perfusion with 600 nM CCCP perfusion, the cardiac capacity to trap 
99mTc-MIBI was compromised such that not only was the injected dose not retained, but tracer trapped within 
the heart from prior injections also washed out resulting in calculated retention values lower than baseline 
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(−3.5 ± 3.1% of injected dose, p < 0.05). Perfusing hearts with CCCP for a longer period resulted in no greater 
degree of 99mTc-MIBI washout. The cardiac retention of 99mTc-NOET (42.1 ± 13.4% of ID) was unaffected by 
CCCP infusion at any concentration examined. The ICR for 99mTc-MIBI progressively increased after 5 min-
utes of CCCP infusion from 1.27 ± 0.12 to 3.18 ± 0.53 at 600 nM (p < 0.05), while its amplitude did not change 
(Supplementary Fig. 2). These rates and amplitudes did not change significantly between 5 and 25 minutes of 
CCCP infusion. The FCR for 99mTc-NOET washout and its amplitude were unaffected by CCCP infusion at any 
dose at any time point. There was a trend of increasing SCR with increasing CCCP dose, which only reached 
significance above control values after 25 minutes of infusion with 600 nM CCCP (from 0.004 ± 0.001 to 
0.012 ± 0.002 (p < 0.05); the amplitude of the SCR was unchanged with any dose.
Doxorubicin perfusion. Doxorubicin perfusion caused a dose-dependent loss of cardiac 99mTc-MIBI retention, 
becoming significantly lower than control values at 100 μM, (17.8 ± 0.7 versus 23 ± 3.5% ID, p < 0.05, Fig. 3). This 
increased washout was largely described by increased SCR without a change in its amplitude (Supplementary 
Fig. 3). 99mTc-NOET retention was unaffected by doxorubicin perfusion at any concentration at any time point.
Langendorff hemodynamics. Hemodynamic parameters are shown in Supplementary Fig. 4. Fifty min-
utes of hypoxic buffer perfusion invoked an initial hyperemic response which progressed to an elevated perfusion 
pressure 137% above baseline (p < 0.05), LVEDP increased tenfold, while LVDevP fell to 5% of control. CCCP 
perfusion caused a dose-dependent increase in perfusion pressure, peaking at 160% above baseline with 600 nM, 
with a progressive increase in LVEDP to 110.1 ± 6.1 mmHg and fall in LVDevP to 2.7 ± 2.2 mmHg. Doxorubicin 
perfusion caused a dose-dependent increase in perfusion pressure peaking at 148.7 ± 26.3 mmHg with 100 mM, 
while LVDevP fell to 29.5 ± 12.9 mmHg.
The effect of doxorubicin injection in vivo. Intraperitoneal administration of doxorubicin resulted in a 
dose-dependent thinning of the cardiac septal and posterior ventricular walls 2 weeks later (measured in vivo by 
echocardiography, Table 1). Left ventricular systolic volume progressively increased with increasing doxorubicin 
dose from 50.3 ± 11.6 to 72.7 ± 9.1 (p < 0.05). Ejection fraction and fractional shortening were only affected at 
the highest dose of 10 mg/kg (by 7% and 9.5% respectively p < 0.05, Fig. 4). There were no differences in these 
recorded functional changes between animals assigned to either radiotracer imaging group.
Figure 1. Time-activity curves showing the myocardial clearance/accumulation of 99mTc-MIBI (left) and 99mTc-
NOET (right) during normoxic (top) and hypoxic buffer perfusion (middle). Graphs represent summarised 
data of mean (n = 6) ± SD. *Significantly different from normoxia (p < 0.05).
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10 mg/kg doxorubicin administration induced cytoplasmic vacuolisation and myofibrillar disarray (Fig. 5), 
and a threefold increase in the apparent number of damaged mitochondria per field of view (Fig. 5A). While there 
was a trend of increased mitochondrial area with increasing doxorubicin dose (Fig. 5B), this did not reach statis-
tical significance; neither was there any quantifiable loss of total mitochondrial content when assessed by citrate 
synthase activity (Fig. 5D). Doxorubicin administration led to a progressive depletion of cardiac ATP content 
(Fig. 5C), but this did not reach statistical significance.
When hearts from these doxorubicin-treated animals were excised and Langendorff-perfused with normal 
oxygenated drug-free buffer in the triple γ-detection system, there were no observable differences in their hemo-
dynamic performance (supplemental Fig. 1). However, we observed a dose dependent loss in their capacity to 
retain 99mTc-MIBI (decreasing from 25.4 ± 3.2% in vehicle controls to 20.5 ± 0.3% in the 10 mg/kg treated group 
p < 0.05, Fig. 6).
In parallel groups of animals where cardiac uptake of each tracer in vivo was quantified by cut-and-count 
3 hours after tail vein injection, there was a marked loss of cardiac 99mTc-MIBI retention with increasing doxo-
rubicin dose (from 2.3 ± 0.3 to 0.9 ± 0.2ID/g with 10 mg/kg doxorubicin, p < 0.05, Fig. 7). Cardiac 99mTc-NOET 
retention was unaffected by any dose investigated in either study.
Discussion
We have demonstrated that cardiac 99mTc-MIBI retention is highly sensitive to mitochondrial perturbation 
induced by hypoxia, mitochondrial uncouplers or doxorubicin treatment in the isolated perfused heart. We 
then show that sub-acute doxorubicin administration leads to a measurable loss of cardiac 99mTc-MIBI retention 
in vivo, suggesting that it could be used to report on changes in ΔΨm as a predicator of evolving cardiac injury. For 
this potential to be realized, it would be necessary to correct clinical cardiac 99mTc-MIBI images for the regional 
variations in perfusion which arise naturally or through concomitant cardiovascular disease or injury. To this 
end, we demonstrate for the first time that the cardiac retention and pharmacokinetics of the perfusion tracer 
99mTc-NOET, an uncharged lipophilic complex, are insensitive to the perturbations that affect 99mTc-MIBI, sug-
gesting that it would be suitable for this purpose.
Figure 2. Time-activity curves showing the myocardial clearance/accumulation of 99mTc-MIBI (left) and 99mTc-
NOET (right) during perfusion with increasing concentrations of CCCP. Graphs represent summarised data of 
mean (n = 6) ± SD. *Significantly different from pre-intervention control bolus (p < 0.05).
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While the cardiac biodistribution of 99mTc-MIBI is used extensively clinically to delineate myocardial perfu-
sion, early isolated cell work demonstrated that 90% of its cardiac accumulation is trapped within mitochondria 
according to ΔΨm, and is blockable by metabolic inhibitors like rotenone and ionophores such as FCCP20,29, or 
promoted by mitochondrial hyperpolarization using nigericin30. To determine how 99mTc-MIBI might best be 
used clinically for detecting the development of anthracycline cardiotoxicity, it is essential to characterize the 
kinetics of the tracers in intact myocardium, as reported here. We have demonstrated that cardiac 99mTc-MIBI 
washout increased with hypoxia severity and duration in isolated perfused hearts, and showed a dose-dependent 
loss of cardiac 99mTc-MIBI retention with increasing dose of the ionophore CCCP and doxorubicin. Our results 
are comparable to studies investigating mitochondrial trapping of the lipophilic cation TMRE in FCCP-treated 
isolated hearts using surface fluorescence31,32. Our radiometric signal, however, is not subject to the complications 
of auto-fluorescence and quenching common in fluorescence measurement, or the poor tissue penetration which 
limits the translational potential of optical imaging techniques.
Progressing to rats in vivo, we confirm that we can detect loss of 99mTc-MIBI retention indicative of cardiot-
oxicity two weeks after a single i.p. bolus of doxorubicin. This is unlikely to be a direct 99mTc-MIBI-doxorubicin 
interaction (since doxorubicin has a half-life of 17.9 and 17.7 hours in plasma and cardiac tissue respectively33), 
but rather the mitochondrial perturbation caused by the initial doxorubicin insult. While mitochondrial disar-
ray was evident by electron microscopy at the highest dose of 10 mg/kg, there was no measurable loss of cardiac 
citrate synthase activity at any dose used, suggesting that 99mTc-MIBI washout was not caused by loss of mito-
chondrial number. There was a modest loss of cardiac ATP which did not reach statistical significance even at the 
top dose of doxorubicin used, highlighting the ability to detect subtle mitochondrial dysfunction which precedes 
Figure 3. Time-activity curves showing the myocardial clearance/accumulation of 99mTc-MIBI (left) and 99mTc-
NOET (right) during perfusion with increasing concentrations of doxorubicin. Graphs represent summarised 
data of mean (n = 6) ± SD. *Significantly different from pre-intervention control bolus (p < 0.05).
www.nature.com/scientificreports/
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or is at a level below that which can be measured by existing functional/biophysical techniques. We demonstrate 
loss of cardiac 99mTc-MIBI retention with all doxorubicin dosages used, which although only reaching statistical 
significance at the highest dose of 10 mg/kg in this small proof of concept study, we believe is attributable to the 
variability in cardiotoxic injury induced by a single intraperitoneal injection, rather than variability in our ability 
to measure it. In our ongoing work we are refining our doxorubicin administration methodology to improve its 
reproducibility, but this does underline the clinical problem: it is difficult to predict which individuals will exhibit 
cardiotoxicity following anthracycline administration (and to what degree), even when an identical dosing regime 
is used. Personalized predictors of evolving cardiac injury in response to anthracyclines are essential.
The dynamic range of 99mTc-MIBI washout in response to doxorubicin was greater when measured by organ 
counting after in vivo injection than when measured using the triple γ-detection system. There are two possible 
reasons for this: first, the isolated heart experiments have rapid first pass perfusion (100 μl into a coronary flow of 
14 ml/min), with no tracer recirculation. As such, the time available for tracer to enter myocytes, transit to mito-
chondria and equilibrate according to ΔΨm is very short, meaning that differential uptake between mitochondria 
at different energy states may be limited by tracer kinetics. In vivo, where coronary flow is slower (~3 ml/min), 
Figure 4. Graphs showing changes in fractional shortening (left) and ejection fraction (right) two weeks after 
intraperitoneal injection of doxorubicin. Mean ± SD. n = 4–6 *significantly different from pre-intervention 
control values (p < 0.05).
LVIDs (mm) LVIDd (mm) IVSs (mm) IVSd (mm) LVPWs (mm) LVPWd (mm)
Baseline (99mTc-MIBI)
0 mg/kg 3.73 ± 0.16 6.56 ± 0.29 2.86 ± 0.15 1.72 ± 0.19 2.40 ± 0.26 1.71 ± 0.25
1 mg/kg 3.76 ± 0.33 6.53 ± 0.37 3.04 ± 0.19 1.94 ± 0.09 2.50 ± 0.34 1.67 ± 0.26
5 mg/kg 3.70 ± 0.51 6.33 ± 0.48 3.13 ± 0.32 1.85 ± 0.10 2.54 ± 0.28 1.74 ± 0.20
10 mg/kg 3.34 ± 0.67 6.20 ± 0.65 2.77 ± 0.20 1.68 ± 0.24 2.53 ± 0.26 1.86 ± 0.13
Baseline (99mTc-NOET)
0 mg/kg 3.44 ± 0.57 6.37 ± 0.65 3.05 ± 0.25 1.75 ± 0.11 2.81 ± 0.27 2.11 ± 0.51
1 mg/kg 3.38 ± 0.32 6.31 ± 0.19 2.93 ± 0.21 1.96 ± 0.23 2.76 ± 0.20 1.86 ± 0.10
5 mg/kg 3.26 ± 0.60 5.93 ± 0.58 3.27 ± 0.25 2.26 ± 0.26 2.54 ± 0.15 1.79 ± 0.14
10 mg/kg 3.16 ± 0.48 6.10 ± 0.27 3.34 ± 0.14 2.08 ± 0.29 2.68 ± 0.12 2.05 ± 0.26
Week 2 (99mTc-MIBI)
0 mg/kg 3.45 ± 0.34 6.10 ± 0.36 2.74 ± 0.03 1.77 ± 0.10 2.56 ± 0.21 2.01 ± 0.22
1 mg/kg 3.77 ± 0.44 6.23 ± 0.14 2.88 ± 0.17 2.04 ± 0.21 2.44 ± 0.23 1.90 ± 0.20
5 mg/kg 4.10 ± 0.39* 6.31 ± 0.57 2.90 ± 0.53 1.58 ± 0.09* 2.47 ± 0.26 1.91 ± 0.24
10 mg/kg 4.31 ± 0.52* 6.76 ± 0.58 2.93 ± 0.12* 1.52 ± 0.14* 2.19 ± 0.33 1.65 ± 0.11*
Week 2 (99mTc-NOET)
0 mg/kg 3.12 ± 0.25 6.02 ± 0.22 2.99 ± 0.25 1.81 ± 0.11 2.68 ± 0.08 2.06 ± 0.26
1 mg/kg 3.47 ± 0.45 6.10 ± 0.44 2.77 ± 0.10 1.81 ± 0.18 2.52 ± 0.18 1.91 ± 0.09
5 mg/kg 3.60 ± 0.79 6.07 ± 0.68 2.55 ± 0.24* 1.79 ± 0.28* 2.18 ± 0.52 1.66 ± 0.25
10 mg/kg 4.11 ± 0.31* 6.96 ± 0.33* 2.68 ± 0.22* 1.72 ± 0.09* 2.33 ± 0.29* 1.73 ± 0.05*
Table 1. Changes in Cardiac geometry due to doxorubicin treatment. Left ventricular internal dimension at 
systole (LVIDs); Left ventricular internal dimension at diastole (LVIDd); Intraventricular septum at systole 
(IVSs); Intraventricular septum at diastole (IVSd); Left ventricular posterior wall at systole (LVPWs); Left 
ventricular posterior wall at diastole (LVPWd); *P < 0.05 versus baseline value by t-test, n = 4–5.
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and the tracer bolus is likely more prolonged (with the opportunity for second pass uptake as the tracer recircu-
lates), there may be greater tracer uptake and equilibration according to ΔΨm, providing a greater dynamic range 
of measurement. Second, 99mTc-MIBI is a known substrate of P-glycoprotein (PgP), which plays a role in pump-
ing the tracer from the cell34. Cardiac PgP levels have recently been shown to be upregulated by anthracycline 
treatment35, which may represent a secondary anthracycline-dependent mechanism removing 99mTc-MIBI from 
the heart. As there was 3 hours between tracer injection and post-mortem biodistribution, this effect may have a 
greater effect on cardiac 99mTc-MIBI retention when measured in vivo compared to the isolated heart. The role of 
PgP in cardiac 99mTc-MIBI washout in vivo warrants further investigation in this context.
Accelerated cardiac 99mTc-MIBI washout kinetics have been reported in patients with dilated cardiomyopathy 
and hypertrophic myopathy36, suggesting that this approach may be sufficiently sensitive to detect cardiac mito-
chondrial dysfunction clinically. A small (16 patient/group) retrospective clinical trial has explored the potential 
of using 99mTc-MIBI to detect chemotherapeutic cardiotoxicity. The authors reported higher cardiac 99mTc-MIBI 
retention in cancer patients post chemotherapy than in their control group, suggesting that chemotherapy led 
to mitochondrial hyperpolarization37 (in contrast to the historic literature cited above, and our current data). 
However, since the “control” group used in this study were patients undergoing assessment for suspected ischae-
mic heart disease (rather than healthy controls), it is likely that their hearts were more compromised than the 
chemotherapy treatment group itself, which may explain the disparity. The author also notes several chemother-
apy patients with fixed (12%) and reversible (44%) perfusion defects in his cohort, which would likely impact 
on the sensitivity of the approach to detect mitochondrial dysfunction, underlining the potential importance of 
perfusion correction in the interpretation of 99mTc-MIBI data used for this purpose.
To ameliorate this common problem of coexisting perfusion defects, we propose that the sensitivity and spec-
ificity of the approach in general could be enhanced by performing sequential or simultaneous scans for mito-
chondrial perturbation and perfusion. 99mTc-NOET is a neutral lipophilic complex designed for cardiac perfusion 
imaging based on its lipophilic retention in cell membranes38,39. Subcellular biodistribution studies have revealed 
that it can diffuse and localize into hydrophobic components of myocardial cells (but not mitochondria), suggest-
ing that once taken into the cell, it becomes trapped within intracellular liposomes39. In vivo studies in rats, dogs 
and monkeys have demonstrated that it is rapidly extracted by the myocardium proportional to regional blood 
flow21,40. Our data go on to demonstrate that 99mTc-NOET is remarkably insensitive to all of the interventions 
to which 99mTc-MIBI responds (hypoxia, ΔΨm collapse, and doxorubicin administration ex vivo and in vivo). 
Furthermore, since we observed no change in cardiac 99mTc-NOET retention in any animals treated with doxo-
rubicin at any dose, it confirms that the observed changes in 99mTc-MIBI retention were not caused by decreased 
tracer delivery through loss of perfusion. As such, 99mTc-NOET is well suited to being used as a comparative 
agent for correcting for regional variations in perfusion to unmask mitochondrially-dependent loss of 99mTc-MIBI 
retention.
Figure 5. (Left) Electron micrographs showing representative damage in hearts two weeks after administration 
of each dose of doxorubicin. (A) Summarised quantification of % mitochondria damaged and (B) average 
mitochondrial area in the field of view (60 images per heart), (C) total cardiac ATP levels and citrate synthase 
activity in the same hearts. Mean ± SD. n = 4–6. *Significantly different from vehicle controls (p < 0.05).
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We propose 99mTc-MIBI and 99mTc-NOET as an initial proof-of-principle pairing due to the widespread clini-
cal use of 99mTc-MIBI. However, there is scope for refinement to our approach. Dual isotope imaging could allow 
ΔΨm and perfusion measurements to be performed in a single scanning session by co-injecting an uncharged 
Figure 6. Time-activity curves showing the myocardial clearance/accumulation of 99mTc-MIBI (left) and 99mTc-
NOET (right) in hearts excised two weeks after intraperitoneal doxorubicin injection, mean (n = 4–5) ± SD. 
*Significantly different from vehicle control (p < 0.05).
Figure 7. Graphs of cardiac retention of 99mTc-MIBI (left) and 99mTc-NOET (right) injection by biodistribution 
two weeks after intraperitoneal doxorubicin injection, mean (n = 4–5) ± SD. *Significantly different from 
vehicle control (p < 0.05).
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lipophilic equivalent of NOET radiolabelled with a different gamma-emitting radioisotope, offering advantages in 
spatiotemporal co-registration of scanning and tracer kinetic information. Our initial curve fitting data in the iso-
lated heart suggest a 17-fold increase in the measured SCR between patent mitochondria and those depolarized 
by hypoxia, suggesting the potential for parameter mapping. The FCR appears insensitive to most interventions 
we studied, and is likely to largely reflect perfusion24. It could therefore possibly be exploited to correct the SCR in 
a single dynamic scan, but this would require further validation and characterization in vivo. While quantifying 
differences between early and late images as a measurement of 99mTc-MIBI washout may be sufficient to crudely 
estimate tracer washout rate, for high temporal resolution measurement of kinetics, SPECT is limited because of 
the time required for the gantry to rotate. This could be mitigated by using dynamic planar scintigraphy at the 
expense of three-dimensional information. However, translation of the approach to PET would provide advan-
tages in sensitivity, spatial resolution, and the native capacity for 3D dynamic imaging and pharmacokinetic mod-
eling. We and others are currently developing lipophilic cationic PET imaging agents (and lipophilic perfusion 
imaging agents as comparators) with sufficiently short half-lives to allow sequential quantification of perfusion 
mitochondrial function in a single scan session; rapidly evolving PET/MR technologies may also provide oppor-
tunities for simultaneous MR perfusion correction of PET data.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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